These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression. Dittloff KT; Iezzi A; Zhong JX; Mohindra P; Desai TA; Russell B Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H149-H160. PubMed ID: 34018852 [TBL] [Abstract][Full Text] [Related]
3. Early transverse tubule involvement in cardiomyocytes in hereditary transthyretin amyloidosis: a possible cause of cardiac events. Misumi Y; Ando Y; Ueda M Cardiovasc Pathol; 2022; 61():107458. PubMed ID: 35872346 [TBL] [Abstract][Full Text] [Related]
4. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812 [TBL] [Abstract][Full Text] [Related]
7. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Ton VK; Mukherjee M; Judge DP Clin Med Insights Cardiol; 2014; 8(Suppl 1):39-44. PubMed ID: 25628512 [TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813 [TBL] [Abstract][Full Text] [Related]
9. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy. Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615 [TBL] [Abstract][Full Text] [Related]
10. A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. George J; Rappaport M; Shimoni S; Goland S; Voldarsky I; Fabricant Y; Edri O; Cuciuc V; Lifshitz S; Tshori S; Fassler M Eur Heart J; 2020 Mar; 41(12):1260-1270. PubMed ID: 31865366 [TBL] [Abstract][Full Text] [Related]
11. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy. Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783 [TBL] [Abstract][Full Text] [Related]
12. Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. Sartiani L; Bucciantini M; Spinelli V; Leri M; Natalello A; Nosi D; Maria Doglia S; Relini A; Penco A; Giorgetti S; Gerace E; Mannaioni G; Bellotti V; Rigacci S; Cerbai E; Stefani M Biophys J; 2016 Nov; 111(9):2024-2038. PubMed ID: 27806283 [TBL] [Abstract][Full Text] [Related]
13. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017 [TBL] [Abstract][Full Text] [Related]
14. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Rosenblum H; Castano A; Alvarez J; Goldsmith J; Helmke S; Maurer MS Circ Heart Fail; 2018 Apr; 11(4):e004769. PubMed ID: 29615436 [TBL] [Abstract][Full Text] [Related]
15. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Cascella R; Conti S; Mannini B; Li X; Buxbaum JN; Tiribilli B; Chiti F; Cecchi C Biochim Biophys Acta; 2013 Dec; 1832(12):2302-14. PubMed ID: 24075940 [TBL] [Abstract][Full Text] [Related]
16. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction. Chen W; Ton VK; Dilsizian V Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480 [TBL] [Abstract][Full Text] [Related]
17. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis). Gonzalez-Duarte A; Ulloa-Aguirre A Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963 [TBL] [Abstract][Full Text] [Related]
18. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism. Si JB; Kim B; Kim JH Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648 [TBL] [Abstract][Full Text] [Related]
19. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076 [TBL] [Abstract][Full Text] [Related]
20. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH. Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]